Enterprise Value

642.5M

Cash

294.6M

Avg Qtr Burn

-39.06M

Short % of Float

26.25%

Insider Ownership

0.39%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IMCIVREE™ (setmelanotide) Details
Proopiomelanocortin deficiency (POMC) deficiency obesity

Approved

Quarterly sales

IMCIVREE™ (setmelanotide) Details
Leptin receptor (LEPR) deficiency obesity

Approved

Quarterly sales

IMCIVREE (Setmelanotide) Details
Rare genetic disease, Bardet-Biedl syndrome

Approved

Quarterly sales

Setmelanotide Details
Alström syndrome

NDA

FDA meeting

Phase 3

Data readout

Phase 2

Interim update